

Supplementary Information


An E3 Aptamer-Modified T Cell-Derived Exosomal
Nanoplatfom for Codelivery of Astragaloside IV and PESV:
Enhancing Prostate Cancer Therapy through Immune
Modulation with Implications for Clinical Translation

Qing Zhang¹, Chenguang Liu², Sirui Wu², Nan Zhong², Junfeng Qiu³, Wei Fu^{4*}, Xujun You^{4*}


This supporting information includes:

Supplementary Figures S1 to S3


Supplementary Table S1



Supplementary Figure. S1 Cellular uptake and cytotoxicity of EAPE in RWPE-1 cells. (A) Cell viability was determined by CCK-8 assay. (B-C) Flow cytometry images and quantitative analysis of cellular uptake in RWPE-1 cells. (D-E) Fluorescence microscopy images and quantitative analysis of cellular uptake in RWPE-1 cells (scale bar: 50 μ m). Data are presented as mean $\pm$ SD (n = 3), statistical significance levels are represented as: *p < 0.05 vs. Control group.



Supplementary Figure. S2 Cellular uptake and cytotoxicity of EAPE in PC-3 cells. (A) Cell viability was determined by CCK-8 assay. (B-C) Flow cytometry images and quantitative analysis of cellular uptake in PC-3 cells. (D-E) Fluorescence microscopy images and quantitative analysis of cellular uptake in PC-3 cells (scale bar: 50 μ m). Data are presented as mean $\pm$ SD (n = 3), statistical significance levels are represented as: *p < 0.05, ***p < 0.001 vs. Control group; ##p < 0.01 vs. AP group.



Supplementary Figure. S3 Cellular uptake and cytotoxicity of EAPE in DU145 cells. (A) Cell viability was determined by CCK-8 assay. (B-C) Flow cytometry images and quantitative analysis of cellular uptake in DU145 cells. (D-E) Fluorescence microscopy images and quantitative analysis of cellular uptake in DU145 cells (scale bar: 50 μ m). Data are presented as mean $\pm$ SD (n = 3), statistical significance levels are represented as: *p < 0.05, **p < 0.01, ***p < 0.001 vs. Control group; #p < 0.05 vs. AP group.

Supplementary Table S1.

Primers used for RT-PCR

Target	Forward Primers,5'-3'	Reverse Primers,5'-3'
<i>PD-1</i>	GCCGCACGAGGGACAATAGGAGCCA	TGAGGTGCCCATTCCGCTAGGAAAGACA
<i>PD-L1</i>	GAACTACCTCTGGCACATCCTCCAA	TTTCACATCCATCATTCTCCCTTTT
<i>GAPDH</i>	GGAAGGTGAAGGTCGGAGTCAACG	TCTCGCTCCTGGAAGATGGTGATGG